70 countries urge N-Korea to scrap nuclear weapons

Paris, Apr 10: French pharma major Sanofi said on Friday it has decided to donate 100 million doses of hydroxychloroquine, the anti-malaria drug which could be a potential weapon against novel coronavirus, across 50 countries.

The company has already doubled its incremental production capacity on top of the usual production for current indications across its eight hydroxychloroquine manufacturing sites worldwide and is on track to quadruple it by the summer.

"In this global health emergency, Sanofi stands ready to assist as many countries as possible, starting with countries where its medicine is registered for current approved indications as well as countries where there are no hydroxychloroquine suppliers or countries with underserved populations," it said in a statement.

Sanofi called for coordination among the entire hydroxychloroquine chain worldwide to ensure the continued supply of the medicine if proven to be a well-tolerated and effective treatment in COVID-19 patients.

"The COVID-19 pandemic is an unprecedented health and economic crisis which is shaking some of the very fundamentals of international solidarity and cooperation among countries," said Chief Executive Officer Paul Hudson. "This virus does not care about the concept of borders, so we should not either," he added.

"It is critical that international authorities, local governments, manufacturers and all other players involved in the hydroxychloroquine chain work together in a coordinated manner to ensure all patients who may benefit from this potential treatment can access it. If the trials prove positive, we hope our donation will play a critical role for patients," said Hudson.

While hydroxychloroquine is generating a lot of hope for patients around the world, said Sanofi, it should be remembered that there are no results from ongoing studies and the results may be positive or negative.

To date, there is insufficient clinical evidence to draw any conclusion over the safety and efficacy of hydroxychloroquine in the management of COVID-19 patients.

It is one of several medicines being investigated by the World Health Organisation (WHO) in its international clinical trial seeking a treatment solution for COVID-19. "Sanofi is supporting ongoing trials by providing the medicine to some participating investigator sites and other independent research centres," it said.

London, May 20: The current physical distancing guidelines of 6 feet may be insufficient to prevent COVID-19 transmission, according to a study which says a mild cough in low wind speeds can propel saliva droplets by as much as 18 feet.

Researchers, including those from the University of Nicosia in Cyprus, said a good baseline for studying the airborne transmission of viruses, like the one behind the COVID-19 pandemic, is a deeper understanding of how particles travel through the air when people cough.

In the study, published in the journal Physics of Fluids, they said even with a slight breeze of about four kilometres per hour (kph), saliva travels 18 feet in 5 seconds.

"The droplet cloud will affect both adults and children of different heights," said study co-author Dimitris Drikakis from the University of Nicosia.

According to the scientists, shorter adults and children could be at higher risk if they are located within the trajectory of the saliva droplets.

They said saliva is a complex fluid, which travels suspended in a bulk of surrounding air released by a cough, adding that many factors affect how saliva droplets travel in the air.

These factors, the study noted, include the size and number of droplets, how they interact with one another and the surrounding air as they disperse and evaporate, how heat and mass are transferred, and the humidity and temperature of the surrounding air.

In the study, the scientists created a computer simulation to examine the state of every saliva droplet moving through the air in front of a coughing person.

The model considered the effects of humidity, dispersion force, interactions of molecules of saliva and air, and how the droplets change from liquid to vapour and evaporate, along with a grid representing the space in front of a coughing person.

Each grid, the scientists said, holds information about variables like pressure, fluid velocity, temperature, droplet mass, and droplet position.

The study analysed the fates of nearly 1,008 simulated saliva droplets, and solved as many as 3.7 million equations.

"The purpose of the mathematical modelling and simulation is to take into account all the real coupling or interaction mechanisms that may take place between the main bulk fluid flow and the saliva droplets, and between the saliva droplets themselves," explained Talib Dbouk, another co-author of the study.

However, the researchers added that further studies are needed to determine the effect of ground surface temperature on the behaviour of saliva in air.

They also believe that indoor environments, especially ones with air conditioning, may significantly affect the particle movement through air.

This work is important since it concerns safety distance guidelines, and advances the understanding of the transmission of airborne diseases, Drikakis said.

Washington, Apr 17: A record number of 4,591 Americans have died in the last 24 hours due to the deadly novel coronavirus in the US, which has the highest number of COVID-19 casualties in the world.

According to the Johns Hopkins University data, by 8 pm on Thursday, as many as 4,591 Americans have died in the last 24 hours, The Wall Street Journal said.

The previous highest was 2,569 on Wednesday.

By Thursday, more than 662,000 Americans tested positive with the coronavirus.

The dreaded disease, which originated in Wuhan city in China in December last year, has so far claimed more than 144,000 lives and infected over 2.1 million people.

The virus has infected over 671,000 people and claimed more than 33,000 lives, the highest for any country in the world.

New York City and its adjoining areas, including New Jersey and Connecticut have emerged as the epicenter of the virus in the US.

New York alone accounts for 226,000 cases of infections and 16,106 deaths.

In New Jersey, as many as 3,518 people have died of the disease and 75,317 have tested positive.

According to the US Centers for Disease Control and Prevention, till April 14, four per cent of the Americans infected with COVID-19 were of Asian origin and nearly one-third (30 per cent) were African Americans.

US President Donald Trump told reporters at the White House that experts and scientists report that his strategy to slow the spread of the virus has saved hundreds of thousands of lives.

Models predicted between 1.5 million and 2.2 million US deaths. If there was no mitigation, it could have even been higher than that and between 100,000 and 240,000 deaths with mitigation. It is looking like we will come far under even these lowest numbers, he said.

Noting that experts say the curve of the virus has flattened, and the peak in the new cases has passed, Trump said that nationwide, more than 850 counties or nearly 30 per cent of the country have reported no new cases in the last seven days.

Because of our early and aggressive action, we have avoided the tragedy of health care rationing and deadly shortfalls that have befallen in many other nations, nations which wherever possible we are helping, he said.

According to Trump, at least 35 clinical trials are already underway, including antiviral therapies, immune therapies, and blood therapies in the form of convalescent plasma. So far, more than 3.5 million tests have been carried out.